Destiny Pharma PLC Director Disclosure (4885I)
03 December 2022 - 1:48AM
UK Regulatory
TIDMDEST
RNS Number : 4885I
Destiny Pharma PLC
02 December 2022
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Director Disclosure
Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology
company focused on the development of novel medicines to prevent
life threatening infections, makes the following disclosure in
relation to Nick Rodgers, Chairman of the Company, pursuant to AIM
Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Productiv Ltd, a company of which Nick Rodgers was part time
director, was placed into liquidation on 18 November 2022. At the
time of liquidation, Productiv had an estimated deficit to
creditors of approximately GBP250,000.
For further information, please contact:
Destiny Pharma plc +44 (0)1273 704 440
Neil Clark, CEO pressoffice@destinypharma.com
Shaun Claydon, CFO
finnCap Ltd (Nominated Adviser and Joint
Broker)
Geoff Nash / Abigail Kelly / George Dollemore,
Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward,
ECM +44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden +44 (0) 20 7408 4090
Optimum Strategic Communications +44 (0) 208 078 4357
Mary Clark / Nick Bastin / Manel Mateus DestinyPharma@optimumcomms.com
MC Services AG
Anne Hennecke / Andreas Burckhardt +49-211-529252-12
Stern IR - US +1-212-362-1200
Janhavi Mohite Janhavi.Mohite@sternir.com
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SporCov, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information on the company, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZMGZDZDGZZM
(END) Dow Jones Newswires
December 02, 2022 09:48 ET (14:48 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024